Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 3, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Previous Holding: 17,271,622 ADRs
- New Holding: 17,308,251 ADRs
- Change Date: December 29, 2006
- Average Price: $52.54
The increase resulted from a movement in the fund. Two directors, Dr. J.P. Garnier and Dr. M.M. Slaoui, are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses the notification of the transaction under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of ADRs held by the US Retirement Savings Plan as of December 29, 2006.
- Confirm the average transaction price of $52.54 for the fund movement.
- Review the specific interests of Directors Dr. J.P. Garnier and Dr. M.M. Slaoui in the discretionary fund.
- Note that this filing does not contain financial performance data for the period.